Anmelden Kostenlos registrieren

Cellectis leerverkaufte Aktien zu allen Aktien

Was ist das leerverkaufte Aktien zu allen Aktien von Cellectis?

leerverkaufte Aktien zu allen Aktien von Cellectis ist 7.02

Was ist die Definition von leerverkaufte Aktien zu allen Aktien?



Das Leerverkauf-Verhältnis ist die Anzahl der leervekauften Aktien geteilt durch das durchschnittliche tägliche Volumen.

Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.

The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.

leerverkaufte Aktien zu allen Aktien von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Cellectis

Was macht Cellectis?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Unternehmen mit leerverkaufte aktien zu allen aktien ähnlich Cellectis